Residency · Residency · Anesthesiology
Neuromuscular Blockade: Depolarizing vs. Non-Depolarizing Agents
Neuromuscular Junction Physiology
Normal Transmission
At the neuromuscular junction, the motor nerve terminal releases acetylcholine (ACh) vesicles into the synaptic cleft. ACh then binds to nicotinic receptors on the motor end plate — specifically, both alpha subunits must be occupied for the channel to open. Sodium influx through the opened channel generates an end-plate potential, and if threshold is reached, a muscle action potential propagates along the fiber. ACh is rapidly hydrolyzed by acetylcholinesterase in the synaptic cleft, terminating the signal. The normal NMJ has a massive ACh reserve — a built-in safety margin — so clinical weakness only appears when more than 75-80% of receptors are blocked.
Nicotinic Receptor Structure
The nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel composed of two alpha-1 subunits, one beta, one delta, and one epsilon (in adults) or gamma (in fetal/denervated muscle) subunit. Fetal (gamma-containing) receptors are found in extrajunctional areas and are particularly prominent in states of denervation, burns, and prolonged immobilization. These extrajunctional receptors have longer open times and heightened sensitivity to succinylcholine, which is the basis for the dangerous hyperkalemic response seen in these conditions.
Depolarizing Agents: Succinylcholine
Pharmacology
Succinylcholine is essentially two ACh molecules linked together. It mimics ACh at the nicotinic receptor, producing a Phase I (depolarizing) block: it binds both alpha subunits, opens the channel, causes an initial depolarization (seen clinically as fasciculations), and then produces sustained depolarization that prevents repolarization and blocks further neuromuscular transmission. Its onset is 30-60 seconds IV — the fastest of all neuromuscular blocking agents. Duration is ultra-short at 5-10 minutes. It is rapidly hydrolyzed by plasma cholinesterase (pseudocholinesterase or butyrylcholinesterase), not by acetylcholinesterase. The ED95 is 0.3 mg/kg, and the intubating dose is 1-1.5 mg/kg (3-5 times the ED95 for rapid onset). An IM dose of 4-5 mg/kg (onset 3-4 minutes) is useful in pediatric emergencies without IV access.
Phase II Block
With repeated or prolonged succinylcholine administration (total exceeding 5-7 mg/kg), a Phase II block can develop. Its characteristics resemble non-depolarizing block: fade on TOF and post-tetanic potentiation. The mechanism involves desensitization — a receptor conformational change that prevents ion flux despite agonist binding. This is clinically uncommon with modern single-dose practice.
Side Effects and Complications
Hyperkalemia
Normally, succinylcholine raises serum potassium by 0.5-1.0 mEq/L from depolarization of skeletal muscle. Dangerous, potentially lethal hyperkalemia occurs when extrajunctional (fetal) nicotinic receptors are upregulated. This happens in burns (beginning 24-48 hours post-burn, with risk persisting for months to years), denervation injuries (spinal cord injury, stroke, Guillain-Barre syndrome — risk from 24-72 hours extending to 6 or more months), prolonged immobilization or ICU myopathy, crush injuries (where hyperkalemia comes from muscle breakdown rather than receptor changes), and upper and lower motor neuron disease. In renal failure, succinylcholine is not absolutely contraindicated if baseline potassium is normal, because the 0.5 mEq/L rise is rarely clinically significant. Cardiac arrest from hyperkalemia is treated with calcium, insulin and glucose, bicarbonate, and hyperventilation.
Cardiac Effects
Succinylcholine can cause sinus bradycardia through muscarinic stimulation at the SA node, especially with repeated doses or in children. Junctional rhythms and, rarely, asystole (especially in children) can occur. Pretreatment with atropine 0.02 mg/kg is advisable if repeat dosing is planned.
Malignant Hyperthermia
Succinylcholine is a known trigger for MH in susceptible individuals, and the risk increases when combined with volatile agents. It is absolutely contraindicated in known or suspected MH susceptibility.
Masseter Muscle Rigidity (MMR)
Jaw tightness after succinylcholine is classified by severity. Mild MMR is common in children (incidence 0.3-1%). Severe MMR — "jaw of steel" — may herald malignant hyperthermia. When severe MMR occurs, volatile agents should be discontinued, the patient observed for MH signs, and dantrolene considered.
Increased Intraocular Pressure
Succinylcholine causes a transient IOP increase of 5-10 mmHg lasting 5-10 minutes. In open globe injury, there is a theoretical risk of vitreous extrusion. Succinylcholine is traditionally avoided in this setting, but when aspiration risk from a difficult airway outweighs the IOP risk, clinical judgment must guide the decision.
Increased Intragastric Pressure
Fasciculation of the abdominal wall increases intragastric pressure, but succinylcholine simultaneously increases lower esophageal sphincter tone. The net aspiration risk is likely unchanged because barrier pressure is maintained.
Myalgias
Postoperative myalgias occur in 10-80% of patients, especially young ambulatory females. They are related to fasciculations and uncoordinated muscle contraction. Pretreatment options include a small defasciculating dose of a non-depolarizing agent, lidocaine, or simply avoiding succinylcholine.
Pseudocholinesterase Deficiency
Heterozygous atypical pseudocholinesterase produces a mildly prolonged block (20-30 minutes), while homozygous atypical enzyme causes a profoundly prolonged block (4-8 hours). The incidence is 1:480 for heterozygous and 1:3200 for homozygous. Diagnosis is made by the dibucaine number: a normal enzyme shows 80% inhibition (dibucaine number 80), heterozygous atypical shows 40-60%, and homozygous atypical shows 20%. Management of prolonged block is supportive — maintain sedation and ventilation until recovery. Neostigmine should not be given (it is a Phase I block), and sugammadex does not work (it only encapsulates aminosteroids). Other causes of reduced pseudocholinesterase include liver disease, pregnancy, malnutrition, organophosphate exposure, plasmapheresis, and certain medications such as echothiophate eye drops.
Non-Depolarizing Agents
Mechanism
Non-depolarizing agents are competitive antagonists at the nicotinic receptor alpha subunits. They occupy one or both alpha subunits without opening the channel, preventing ACh from binding and generating an end-plate potential. Their characteristics include fade on TOF, post-tetanic potentiation, and the absence of fasciculations.
Classification
Aminosteroid Compounds
| Agent | ED95 | Intubating Dose | Onset | Clinical Duration | Metabolism |
|---|---|---|---|---|---|
| Rocuronium | 0.3 mg/kg | 0.6-1.2 mg/kg | 60-90 sec | 30-45 min | Hepatic (70%), renal (30%) |
| Vecuronium | 0.05 mg/kg | 0.1 mg/kg | 2-3 min | 25-40 min | Hepatic (60-80%); 3-OH metabolite active |
| Pancuronium | 0.07 mg/kg | 0.08-0.1 mg/kg | 3-5 min | 60-90 min | Renal (80%) |
Benzylisoquinolinium Compounds
| Agent | ED95 | Intubating Dose | Onset | Clinical Duration | Metabolism |
|---|---|---|---|---|---|
| Cisatracurium | 0.05 mg/kg | 0.15-0.2 mg/kg | 3-5 min | 30-40 min | Hofmann elimination (77%), ester hydrolysis |
| Atracurium | 0.25 mg/kg | 0.4-0.5 mg/kg | 2-3 min | 25-35 min | Hofmann elimination, ester hydrolysis |
| Mivacurium | 0.08 mg/kg | 0.15-0.25 mg/kg | 2-3 min | 15-20 min | Plasma cholinesterase |
Agent-Specific Details
Rocuronium
Rocuronium is the most commonly used non-depolarizing agent in modern practice. At high doses (1.2 mg/kg), it achieves intubating conditions in 60 seconds and can replace succinylcholine for RSI. It can be reversed with sugammadex even from profound block (using the 16 mg/kg dose). It has a vagolytic effect that is minimal at standard doses but may produce mild tachycardia at high doses. Duration is prolonged in hepatic dysfunction. Its key advantage is the fastest onset of all non-depolarizing agents combined with full reversibility through sugammadex.
Vecuronium
Vecuronium is an intermediate-duration agent with minimal cardiovascular effects. It is supplied as a lyophilized powder requiring reconstitution. Its active metabolite 3-desacetylvecuronium accumulates in renal failure, leading to prolonged block. It can be reversed with sugammadex because it is an aminosteroid.
Cisatracurium
Cisatracurium undergoes organ-independent Hofmann degradation — a spontaneous breakdown that is pH- and temperature-dependent. This makes it ideal for patients with combined hepatic and renal failure. Unlike atracurium at higher doses, it does not release histamine. Its metabolite laudanosine has CNS excitatory potential, but levels are lower than with atracurium and clinically insignificant.
Pancuronium
Pancuronium is a long-acting agent with vagolytic properties that produce tachycardia. It was historically used in cardiac surgery. Because elimination is predominantly renal, its effect is prolonged in renal failure. It has largely been replaced by shorter-acting agents but is still used when prolonged paralysis is desired.
Monitoring Neuromuscular Blockade
Neuromuscular monitoring is covered in detail in the dedicated topic on quantitative monitoring. The key point is that clinical assessment alone is unreliable — a TOF ratio greater than 0.9 is required for safe extubation, and this should be confirmed with acceleromyography or electromyography.
<image>A detailed anatomical diagram of the neuromuscular junction showing: the motor nerve terminal with ACh vesicles, voltage-gated calcium channels, and synaptic release; the synaptic cleft with acetylcholinesterase enzymes; and the postsynaptic motor end plate with nicotinic receptors (pentameric structure labeled with alpha, beta, delta, epsilon subunits). Arrows show where depolarizing agents (succinylcholine) and non-depolarizing agents (rocuronium) act. Inset shows the difference between junctional and extrajunctional receptor distribution in normal versus denervated muscle.</image>
<image>A clinical comparison chart of succinylcholine versus high-dose rocuronium for rapid sequence induction: onset time, intubating conditions at 60 seconds, duration of action, reversal options (none vs. sugammadex), side effect profiles (fasciculations, hyperkalemia, MH trigger vs. none), and clinical scenarios where each is preferred. A decision tree at the bottom guides agent selection based on patient factors (MH risk, hyperkalemia risk, anticipated difficult airway, available reversal agents).</image>
<image>A train-of-four monitoring diagram showing four electrical stimuli delivered at 2 Hz to the ulnar nerve with corresponding thumb adduction responses for: (1) no block (four equal twitches, ratio 1.0), (2) depolarizing Phase I block (four equal but diminished twitches, no fade), (3) non-depolarizing block at various depths (progressive fade: 4/4, 3/4, 2/4, 1/4, 0/4 twitches with percentage receptor occupancy for each), and (4) Phase II block (fade pattern resembling non-depolarizing block).</image>
Clinical Pearls
Succinylcholine remains the fastest-onset neuromuscular blocker (30-60 seconds), and high-dose rocuronium (1.2 mg/kg) is the best alternative for RSI, especially when sugammadex is available for reversal. The hyperkalemia risk with succinylcholine in burns and denervation begins at 24-72 hours post-injury and may persist for 6 months to years — the timing is critical. The dibucaine number identifies the type (quality) of pseudocholinesterase, not the amount (quantity); a low dibucaine number indicates an atypical enzyme. Cisatracurium is the ideal non-depolarizing agent for multi-organ failure because Hofmann elimination is organ-independent. The combination of rocuronium plus sugammadex has fundamentally changed RSI practice by providing rapid-onset paralysis with a reliable escape plan if intubation fails. Fasciculations from succinylcholine increase oxygen consumption and can worsen hyperkalemia; defasciculation with a small dose of rocuronium (0.06 mg/kg) given 2-3 minutes beforehand can reduce but not eliminate these effects.
References
- Naguib M, et al. Pharmacology of neuromuscular blocking drugs. In: Miller RD, ed. Miller's Anesthesia, 9th edition.
- Martyn JA, et al. Up-and-down regulation of skeletal muscle acetylcholine receptors: effects on neuromuscular blockers. Anesthesiology. 1992;76(5):822-843.
- Tran DT, et al. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev. 2015;10:CD002788.
- Lee C. Structure, conformation, and action of neuromuscular blocking drugs. Br J Anaesth. 2001;87(5):755-769.
- Viby-Mogensen J. Succinylcholine neuromuscular blockade and pseudocholinesterase. Dan Med Bull. 1983;30(3):129-150.
